The cross-over of statistical thinking and practices: A pandemic catalyst.
Pharm Stat
; 21(4): 778-789, 2022 07.
Article
in English
| MEDLINE | ID: covidwho-1930084
ABSTRACT
Written during the SARS-CoV-2 pandemic, and in recognition of Andy Grieve, the polymath, this article looks at an eclectic mix of topics where statistical thinking and practices should transcend typical dividing lines-with a particular focus on the areas of drug development, public health and social science. The case is made for embedding an experimental (or quasi-experimental) framework within clinical practice for vaccines and treatments following their marketing authorisation. A similar case is made for public health interventions-facilitated by pre-specification of effect size and by the greater use of data standards. A number of recommendations are made whilst noting that progress is being made in some areas.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pandemics
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Pharm Stat
Journal subject:
Pharmacology
Year:
2022
Document Type:
Article
Affiliation country:
Pst.2221
Similar
MEDLINE
...
LILACS
LIS